Protara Therapeutics, Inc. (TARA)
3.965
+0.02
(+0.63%)
USD |
NASDAQ |
Sep 03, 16:00
3.965
0.00 (0.00%)
After-Hours: 18:14
Protara Therapeutics Cash from Investing (Quarterly) : 17.75M for June 30, 2026
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 17.75M |
| March 31, 2026 | -14.72M |
| December 31, 2025 | -26.91M |
| September 30, 2025 | -6.506M |
| June 30, 2025 | -47.72M |
| March 31, 2025 | -58.35M |
| December 31, 2024 | 22.50M |
| September 30, 2024 | -29.39M |
| June 30, 2024 | 2.945M |
| March 31, 2024 | 23.10M |
| December 31, 2023 | 14.52M |
| September 30, 2023 | 6.378M |
| June 30, 2023 | 22.35M |
| March 31, 2023 | 9.86M |
| December 31, 2022 | -18.34M |
| September 30, 2022 | 19.05M |
| June 30, 2022 | 13.50M |
| March 31, 2022 | 0.745M |
| December 31, 2021 | 1.889M |
| September 30, 2021 | 0.107M |
| June 30, 2021 | -1.941M |
| March 31, 2021 | -98.25M |
| December 31, 2020 | -0.5104M |
| September 30, 2020 | -0.1321M |
| June 30, 2020 | 0.0058M |
| Date | Value |
|---|---|
| March 31, 2020 | 3.472M |
| December 31, 2019 | -0.0459M |
| September 30, 2019 | -0.3254M |
| June 30, 2019 | -0.0766M |
| March 31, 2019 | -0.0271M |
| December 31, 2018 | 5.413M |
| September 30, 2018 | 6.003M |
| June 30, 2018 | -2.494M |
| March 31, 2018 | 9.505M |
| December 31, 2017 | 6.447M |
| September 30, 2017 | -14.09M |
| June 30, 2017 | -13.37M |
| March 31, 2017 | 4.914M |
| December 31, 2016 | 15.33M |
| September 30, 2016 | -0.906M |
| June 30, 2016 | 15.61M |
| March 31, 2016 | -10.12M |
| December 31, 2015 | 9.218M |
| September 30, 2015 | 23.06M |
| June 30, 2015 | 11.58M |
| March 31, 2015 | -55.18M |
| December 31, 2014 | 3.679M |
| September 30, 2014 | -1.686M |
| June 30, 2014 | -16.83M |
| March 31, 2014 | 2.355M |
Cash From Investing Definition
Represents the net cash flow from the company's investing activities. Investing activities represent the movement in the company's long-term assets.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| NovelStem International Corp. | 0.00 |
| Brainstorm Cell Therapeutics, Inc. | 0.00 |
| Summit Therapeutics, Inc. | 222.41M |
| Kezar Life Sciences, Inc. | 1.529M |
| Clene, Inc. | -0.001M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -15.39M |
| Cash from Financing (Quarterly) | -0.026M |
| Free Cash Flow | -66.49M |
| Free Cash Flow Per Share (Quarterly) | -0.2577 |
| Free Cash Flow to Equity (Quarterly) | -15.41M |
| Free Cash Flow to Firm (Quarterly) | -15.72M |
| Free Cash Flow Yield | -32.43% |